What is the J-Test?

How Does Jericho’s J-Test Compare with the Current Gold Standard?

There is no clinical assay for the reservoir.

─ RF Siliciano, July 2013 (Curr Opin HIV AIDS; 8(4): 318-325) p.322 second paragraph

While combination anti-retroviral drugs (cART) can control active HIV-1 virus replication, they are not “curative”. Rather, these drugs are required life-long. Therefore, longer term and “curative” therapeutic approaches are being explored. Developing newer therapeutic strategies that can reduce or clear persistent, underlying sources of virus infection will require novel clinical diagnostic assays and tools. Such tools must comprehensively evaluate virologic, immunologic and safety parameters for individuals who may require personalized therapies.

Our results indicate that no single in vitro cell model alone is able to capture accurately the ex vivo response characteristics of latently infected T cells from patients.

─ CA Spina, Dec 2013 (PLoS Pathog.;9(12): e1003834) Abstract

Jericho Sciences is developing a clinically relevant, diagnostic assay for personalized clinical management of “curative” therapeutic strategies for HIV-1 infection. Our patent-pending technology assesses patient-specific responses across comparative conditions using multiparametric measures from the full peripheral blood immunologic compartment. Most other assays exclude cells other than CD4 T cells. Jericho’s assay more accurately reflects the natural environment of CD4 T cells by using whole blood.

The J-Test Model

While useful for research, the current gold standard, the Quantitative Viral Outgrowth Assay (QVOA) is expensive, labor intensive, highly variable, takes several weeks to complete and requires large volumes of blood. To date, the QVOA has failed to accurately predict clinical success of candidate therapeutics intended to reduce persistent sources of HIV virus. 

Jericho’s J-Test Value Proposition

  • Requires small volumes of blood for comparative tests
  • Internally-referenced, patient-specific responses
  • Results in less than one week
  • Full peripheral immunologic compartment
  • Provides cellular, viral, immunologic and safety parameters
  • Appropriate model for HIV-1 “curative” therapeutic testing
  • Identification of biomarkers
  • Clinically relevant